A Randomized, Controlled, Multicenter Trial of Levamlodipine Besylate Versus Amlodipine Maleate in Patients With Essential Hypertension

NCT01131546 Phase 4 COMPLETED

This study is designed to compare the safety and efficacy of levamlodipine besylate (2.5mg or 5mg) versus amlodipine maleate (5mg) in patients with mild to moderate essential hypertension.

Details

Lead sponsor	Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase	Phase 4
Status	COMPLETED
Enrolment	1080
Start date	2009-12
Completion	2011-03

Conditions

• Essential Hypertension

Interventions

• Levamlodipine besylate
• Amlodipine maleate

Primary outcomes

• Proportion of patients who reach overall blood pressure control (defined as BP <140/90 mmHg for non-diabetic patients and < 130/80 mmHg for diabetic patients) — Week 8

Countries

China